Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Dementia Associated With Cerebrovascular Disease

Conditions

Dementia Associated With Cerebrovascular Disease

Trial Timeline

Aug 5, 2013 โ†’ Dec 21, 2018

About Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride

Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride is a approved stage product being developed by Eisai for Dementia Associated With Cerebrovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02660983. Target conditions include Dementia Associated With Cerebrovascular Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02660983ApprovedCompleted

Competing Products

20 competing products in Dementia Associated With Cerebrovascular Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 3
69
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
ATH-1017 + PlaceboLeonaBioPhase 2
44
IGC AD1 + PlaceboIGC PharmaPhase 1
25
E2020 + PlaceboEisaiApproved
85
ARICEPTEisaiPhase 3
77
RasagilineEisaiPhase 2
52
Donepezil HydrochlorideEisaiPre-clinical
23
donepezil hclEisaiPhase 3
77
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
77
E2020 + E2020EisaiPhase 2
52
donepezil hydrochloride (Aricept)EisaiApproved
85
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
52
E2020 + E2020EisaiPhase 3
77
Irsenontrine + PlaceboEisaiPhase 2
52
E2020EisaiPhase 2
52
MecobalaminEisaiApproved
85
E2020 + PlaceboEisaiPhase 3
77
Donepezil HydrochlorideEisaiPhase 3
77